Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 32Myelodysplastic Syndromes 20Leukemia, Myelomonocytic, Chronic 12Myeloproliferative Disorders 2Leukemia, Biphenotypic, Acute 2Systemic Mastocytosis With an Associated Hematologic Neoplasm 1Patient Preference 1Neoplasms 1Myelodysplastic-Myeloproliferative Diseases 1Multiple Myeloma 1Leukemia, Myeloid, Chronic-Phase 1GATA2 Deficiency 1Colorectal Neoplasms 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Azacitidine 5venetoclax 4Specimen Handling 3Nivolumab 2regorafenib 1midostaurin 1iadademstat 1fludarabine phosphate 1fludarabine 1decitabine and cedazuridine drug combination 1Whole-Body Irradiation 1Vorinostat 1Thiotepa 1Tacrolimus 1Methotrexate 1Lenalidomide 1Injections 1Decitabine 1Cytarabine 1Cyclophosphamide 1Busulfan 1Bone Marrow Transplantation 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
GATA2 Deficiency × decitabine and cedazuridine drug combination × Other hematologic neoplasm × Clear all
NCT06484062 2026-05-13

Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

National Cancer Institute (NCI)

Phase 1 Recruiting
54 enrolled
MyeloidOther hematologic neoplasm

GATA2 Deficiency, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡